Table 4.

CETP V405 Genotype and Risk for Dementia and Alzheimer’s Disease^a

Category	Model 1b		Model 2c		Model 3d
	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Risk for Dementia Comparing Valine Heterozygotes, Carriers and Homozygotes to Isoleucine Homozygotes
Valine Heterozygotes n=16	0.52 (0.26 – 1.06)	0.07	0.53 (0.26 – 1.09)	0.08	0.57 (0.28 – 1.15)	0.12
Valine Homozygotes n=5	0.29 (0.10 –0.85)	0.02	0.28 (0.09 – 0.84)	0.02	0.28 (0.10 – 0.85)	0.02
Risk for Alzheimer’s Disease Comparing Valine Heterozygotes, Carriers and Homozygotes to Isoleucine Homozygotes
Valine Heterozygotes n=14	0.52 (0.24 – 1.13)	0.10	0.53 (0.25 – 1.2)	0.11	0.56 (0.26 –1.2)	0.14
Valine Homozygotes n=5	0.31 (0.10 – 0.96)	0.04	0.30 (0.10 – 0.94)	0.04	0.31 (0.10 – 0.95)	0.04

Abbreviations: CI, Confidence Interval; HR, Hazard Ratio.

^aP values from Cox proportional hazard models with delayed entry and age as the time scale. There were 40 incident cases of dementia and 35 incident cases of Alzheimer’s disease. There were 19 individuals in the reference group for dementia and 16 individuals in the reference group for Alzheimer’s disease.

^bAdjusted for sex, years of education, non-Ashkenazi white race, black race.

^cAdjusted for the covariates in Model 1 plus an additional adjustment for medical comorbidities as measured by the Medical Comorbidity Index.

^dAdjusted for the covariates in Model 2 plus an additional adjustment for presence of an APOE ε4 allele.